BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

Fired HHS Official Sparks Confusion Over "Make America Healthy Again" Agenda A top official at the Department of Health and Human Services (HHS) has been fired, igniting a firestorm of controversy and ...